Overall clinical study results
JIDEYTRO showed long-lasting results* for people who previously received 1 to 4 ROS1-targeted therapies, including those who were heavily pretreated
44% overall response rate
Duration of response
69% of people who responded
to treatment (35 out of 51) had results that lasted at least 12 months
The longest duration of response observed in the clinical study with JIDEYTRO was 28.5 months (range of 1.9 to 28.5+ months). At the time of the last study follow-up, the person was still responding to JIDEYTRO.
Because participants had already tried between 1 and 4 ROS1-targeted therapies before JIDEYTRO, the results reflect how the therapy performed in people with advanced treatment histories.
*Long-lasting results are based on the overall response rate and the 12-month duration of response rate in the full study population.
†At least a 30% decrease as measured by Response Evaluation Criteria in Solid Tumors (RECIST) during 2 different tumor evaluations. RECIST is a standard way to measure how well a patient responds to treatment. It is based on whether tumors shrink, stay the same, get bigger, or spread to a new part of the body.
‡A complete response (tumor disappearing) does not mean the cancer has been cured.
Individual treatment results may vary. Talk to your doctor to see if JIDEYTRO may be right for you.
Talk to your doctor to see if JIDEYTRO may be right for you.
Understanding the different ways results are measured
What is overall response rate?
The proportion of people who saw their tumors shrink by at least 30%* or disappear during treatment and follow-up in the clinical study. This includes both partial response and complete response.
What is partial response?
The cancer has shrunk by at least 30%,* and there are no signs that the cancer has grown anywhere else in the body.
What is complete response?
When signs of a tumor have completely disappeared with no evidence of disease visible on scans or other tests. This does not mean the cancer has been cured.
If cancer is in the brain, the results are measured by intracranial overall response rate, intracranial partial response, and intracranial complete response.
What is duration of response?
The length of time that a person keeps living without their cancer progressing, after seeing a complete response or partial response.
*At least a 30% decrease as measured by Response Evaluation Criteria in Solid Tumors (RECIST) during 2 different tumor evaluations. RECIST is a standard way to measure how well a patient responds to treatment. It is based on whether tumors shrink, stay the same, get bigger, or spread to a new part of the body.
Learn about results with JIDEYTRO for brain metastases & ROS1 resistance mutations.
How to take JIDEYTRO
Learn about taking once-daily JIDEYTRO, a medication that can coexist with your routine.
Part of a strong community
Share your experiences and receive support by connecting with advocacy and support groups.
ROS1=ROS proto-oncogene 1.